

ERLYTX ACCRUAL REPORT - OPEN and recently closed STUDIES

STUDY	O R P E E G N ARM	ACCR. GOAL	TOTAL REGS.	REGS.	REGS.	REGS.	REGS.	REGS.	# of ACT. INSTs	# of CURR IRBs
				LAST	LAST	LAST	LAST	LAST		
				12 Month	6 Month	3 Month	30 DAYS	7 DAYS		
S0711-Liver dysfunction PK, Dasatinib	1 Y 1 Grp1, Normal LFT, 140mg	48	17	0	0	0	0	0	8	8
	2 Grp2, C-P Class A(Mild), 100mg		3	0	0	0	0	0		
	3 Grp2, C-P Class A(Mild), 140mg		19	0	0	0	0	0		
	4 Grp3, C-P Class B(Mod), 70mg		4	0	0	0	0	0		
	5 Grp3, C-P Class B(Mod), 100mg		11	1	1	1	0	0		
	6 Grp2b, CP Class A(Mild), 140mg		1	1	1	1	0	0		
	7 Grp4, C-P Class C(Severe), 50mg		1	0	0	0	0	0		
	8 Grp3b, CP Class B(Mod), 100mg		2	2	2	2	1	0		
	10 Grp4b, CP Class C(Severe), 50mg		1	1	1	1	0	0		
			59	5	5	5	1	0		

9 rows selected.

no rows selected